Biotech MavenHot Analyst Reads4 Hot Analyst Reads For Tuesday, June 12thBiotech MavenCellectis SA Receives a Buy from Oppenheimer | Analyst Ratings Oppenheimer analyst Hartaj Singh maintained a Buy rating on Cellectis SA (NASDAQ: CLLS) yesterday and set a price target of $44. The company’s shares closed yesterday at $30.21.www.analystratings.com